Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC - Tonix Pharmaceuticals (NASDAQ:TNXP)

Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) are Indicated for the Treatment of Acute Migraine in Adults Strategic Acquisition Helps Build Tonix's Commercial

Related Keywords

United States ,Americans ,Peter Vozzo ,Ben Shannon ,Gregory Sullivan ,James Hunter ,Zembrace Symtouch ,Jessica Morris ,Seth Lederman ,Tonix Pharmaceuticals Or ,Tonix Medicines Inc ,Operations At Tonix Pharmaceuticals ,Neurelis Inc ,Us Sumatriptan Research Group ,Exchange Commission ,National Sales Perspectives ,Tonix Pharmaceuticals ,Upsher Smith Laboratories ,Tonix Pharmaceuticals Holding Corp ,Aegis Therapeutics ,Us Food Drug Administration ,Acute Migraine ,Acquisition Helps Build Tonix ,Commercial Capabilities ,Infrastructure Ahead ,Potential Launch ,Migraine Products Complement Tonix ,Current Intranasal Clinical Development Program ,Nasal Spray Products ,Gastrointestinal Tract Have ,Provide Treatment Options ,Migraine Associated ,Tonix Pharmaceuticals Holding ,Tonix Medicines ,New Drug Applications ,Drug Administration ,Chief Executive Officer ,Chief Medical Officer ,Executive Vice President ,Commercial Operations ,Maple Grove ,Expert Opinion Drug ,Illness Among People ,Headache Days While Using Acute ,Preventive Prescription Medications ,Managed Care ,Smith Laboratories ,Global Burden ,Disease Study ,Lancet Neurol ,Classification Committee ,International Headache Society ,Patient Information ,Breakthrough Therapy ,Orphan Drug ,Private Securities Litigation Reform Act ,Annual Report ,